Mechera Robert, Viehl Carsten T, Oertli Daniel
Department of Surgery, University Hospital Basel, Basel, Switzerland.
Breast Cancer Res Treat. 2009 Jul;116(1):171-7. doi: 10.1007/s10549-008-0187-y. Epub 2008 Sep 25.
The main objectives of this study were to identify risk factors for local in-breast tumor recurrence after breast-conservation and to evaluate the impact of IBTR (in-breast tumor recurrence) on overall survival.
A total of 335 consecutive patients with 346 invasive and in situ breast cancers were treated with breast conserving therapy. Univariate and multivariate statistical analysis were performed and survival rates were calculated and analyzed using the Kaplan-Meier method.
With a median follow-up period of 70.6 months 14 patients (4%) developed an IBTR. Overall survival and the disease-free 8-year actuarial survival of patients were 95% and 93%, respectively. The overall survival of patients with tumour recurrence on any site was significantly shorter than of those without recurrence (64% versus 85% after 8 years of follow-up; P < 0.0001). Similarly, overall survival was significantly reduced in patients with distant metastases compared to all others without distant disease (88% versus 40% after 8 years; P < 0.0001). In contrast, overall survival of patients who experienced IBTR did not differ significantly from the group of patients who never developed IBTR (87% versus 70% after 8 years of follow-up). By univariate analysis, lobular carcinoma, high grade tumours, multifocality, concomitant LCIS and DCIS, the absence of estrogene and progesterone receptor status, as well as R1-status, were significant predictors of IBTR. By multivariate analysis, only R1-status (P < 0.002) and the presence of LCIS around the invasive tumour (P < 0.03) remained as significant factors predicting IBTR.
Concomitant lobular carcinomas in situ, as well as R1 surgical status are independent significant risk factors for in breast tumor recurrence after breast conserving therapy.
本研究的主要目的是确定保乳术后局部乳腺肿瘤复发的危险因素,并评估乳腺内肿瘤复发(IBTR)对总生存率的影响。
共有335例连续的346例浸润性和原位乳腺癌患者接受了保乳治疗。进行了单因素和多因素统计分析,并使用Kaplan-Meier方法计算和分析生存率。
中位随访期为70.6个月,14例患者(4%)发生了IBTR。患者的总生存率和8年无病精算生存率分别为95%和93%。任何部位出现肿瘤复发的患者的总生存率显著低于未复发的患者(随访8年后分别为64%和85%;P<0.0001)。同样,与所有无远处疾病的其他患者相比,有远处转移的患者的总生存率显著降低(8年后分别为88%和40%;P<0.0001)。相比之下,经历过IBTR的患者的总生存率与从未发生过IBTR的患者组没有显著差异(随访8年后分别为87%和70%)。单因素分析显示,小叶癌、高级别肿瘤、多灶性、合并小叶原位癌(LCIS)和导管原位癌(DCIS)、雌激素和孕激素受体状态缺失以及R1状态是IBTR的显著预测因素。多因素分析显示,只有R1状态(P<0.002)和浸润性肿瘤周围存在LCIS(P<0.03)仍然是预测IBTR的显著因素。
合并小叶原位癌以及R1手术状态是保乳治疗后乳腺内肿瘤复发的独立显著危险因素。